Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Obesity matters for drug developers
Close to 40% of the US adult population is now obese and the WHO and AMA define obesity as a disease. So it’s perhaps no surprise that Evaluate Pharma is forecasting sales by indication of $50bn in 2028 and CAGR between 2021 and 2028 at around 36%. The R&D pipeline is filling up as more and more companies try to grab a slice of this…
Report library
Evaluate Vantage 2022 Preview Report
Covid-19 will still be a front-page story in 2022, keeping the biopharma sector in the spotlight. The attention will bring some benefits, largely in the shape of broad…
Biopharma Quarterly Round Up (Q3 2021)
This article pack, produced by the editorial team at Evaluate Vantage, explores the key developments and decisions that are impacting the biopharma landscape. Access…
Covid Round Up (2021)
The biopharma and medtech sectors have been racing to deliver treatments, vaccines and other solutions to Covid-19 for close to two years now. What progress has been made…
European Society of Medical Oncology Conference (ESMO) 2021
Conducted as a virtual event from 16 to 21 September, ESMO 2021 brought together an international community of experts across disciplines. Once again, this oncology…
2021 IASLC World Conference on Lung Cancer
The year-end oncology congress season kicked off with the annual IASLC World Conference on Lung Cancer. While it took place in virtual format from September 8-14, this…
Evaluate Vantage SPAC article pack Sept 2021
Special purpose acquisition companies, known as Spacs or “blank check companies”, are not new but have recently rocketed in popularity as a vehicle for going public…
Biopharma and Medtech Half-Year Review 2021
Despite the continuing pandemic, the biopharma sector saw a return to relative stability during the first half of 2021. Remote operations are proving effective, deals are…
Evaluate Pharma World Preview 2021, Outlook to 2026
We provide top-level insights and analyses on all the key trends in the fourteenth edition of the Evaluate Pharma World Preview 2021, Outlook to 2026 report. Our most…
Evaluate Pharma World Preview 2021, Outlook to 2026 Infographic
This infographic showcases the key insights from the Evaluate Pharma World Preview, Outlook to 2026 report, at a time when the biopharma sector is under intense…
Evaluate Vantage Biopharma and Venture Capital: A Deep Dive
The sheer amount of private capital available to young drug developers the last few years is nothing new, however the Covid-19 pandemic has brought about an unprecedented…
